Company Buyout Price: Kiniksa Corp (KNSA)

Brandmark of Kiniksa Corp (KNSA)

Kiniksa Pharmaceuticals (KNSA) specializes in developing orphan biologics, facing a niche market and regulatory barriers. The business model's revenue relies on the sale of innovative treatments for autoimmune and cardiovascular pathologies. A high-demand pericarditis drug, which remains highly relevant, serves as a steady cash generator. The price action confirms these data, fixing the Enterprise Value at 7104.57.

KNSA kiniksa.com: Total Company Value in the range 11/23/2025 - 10/30/2026

Kiniksa Pharmaceuticals (KNSA) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price Kiniksa Pharmaceuticals, Ltd.|KNSA - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Kiniksa|KNSA - Enterprise Value
- balance sheet equity data:
Book Value per Share Kiniksa|KNSA - Company Book Value|Market Capitalization to Net Assets kiniksa.com|KNSA - Company Total Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Kiniksa Pharmaceuticals|KNSA - Long-Term Debt to Capital|Short-Term Debt to Capital kiniksa.com|KNSA - Company Debts|Debt to Net Assets Ratio Kiniksa|KNSA - Company Long-Term Debt|Company Current Liabilities Kiniksa|Quick Ratio kiniksa.com
- business earnings and investment ratios data:
KNSA - Net Income
Analysis of all company metrics:Kiniksa Pharmaceuticals, Ltd.
Brand item of Kiniksa Pharmaceuticals

Enterprise Value represents the total capital volume, including market capitalization and net debt, reflecting the actual price for a full buyout of the asset. By analyzing the total business value on GURU.Markets, an investor can see how the exclusive rights to pericarditis drugs and the strong pricing power of Kiniksa Pharmaceuticals (KNSA) justify the company's current valuation relative to its cash flows.

Competitors of Kiniksa Pharmaceuticals (KNSA)

ARGX: Business Value|BNTX - Total Company Value|Company Buyout Price Abivax Pharma ABVX|ADMA: Enterprise Value|protagonist-inc.com (PTGX) - Enterprise Value|Total Company Value Immunovant|Grifols SA - Full Business Value|Enterprise Value ADPT|CLDX (Celldex Corp) - Value Adjusted for Debt and Cash|Enterprise Value AUPH (Aurinia Pharmaceuticals)|Enterprise Value biocryst.com BCRX|VERA - Total Company Value|Value Adjusted for Debt and Cash DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp (PHVS) - Total Company Value|Real Price to Acquire Entire Company AbCellera Biologics Inc.|TRML (Tourmaline Bio, Inc.) - Enterprise Value|Enterprise Value precigen.com|Real Price to Acquire Entire Company PHAR (Pharming Group)|NKTR (Nektar Therapeutics Inc) - Value Adjusted for Debt and Cash|Enterprise Value UPB (Upstream Bio Corp)|Company Buyout Price Zenas Corp (ZBIO)|IMNM - Total Company Value|gossamerbio.com (GOSS) - Real Price to Acquire Entire Company|KalVista Pharmaceuticals, Inc. (KALV) - Total Company Value|Real Price to Acquire Entire Company Septerna, Inc.|Real Price to Acquire Entire Company PVLA|Enterprise Value Savara Pharma|Total Company Value Rigel Pharmaceuticals (RIGL)|anaptysbio.com - Business Value|Enterprise Value ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Total Enterprise Value|RAPT - Total Company Value|JBIO - Enterprise Value|ACRS: Enterprise Value|KYTX - Company Buyout Price|Total Company Value Tiziana Life Sciences Ltd|Business Value CABA (Cabaletta Bio Inc.)|Enterprise Value VTYX|Company Buyout Price Theratechnologies, Inc|Total Company Value Avalo Therapeutics, Inc AVTX|Enterprise Value eledon.com ELDN|AGEN - Total Company Value|Company Buyout Price Climb Bio Inc. CLYM|ZURA: Enterprise Value|aTyr Pharmaceuticals (ATYR) - Enterprise Value|Real Price to Acquire Entire Company ADAG|IMA: Value Adjusted for Debt and Cash|Total Company Value Shattuck Labs, Inc. (STTK)|EQ: Full Business Value|Enterprise Value CNTB (Connect Biopharma Holdings Limited)|Value Adjusted for Debt and Cash IMUX|Atara Biotherapeutics Inc - Enterprise Value|IFRX - Enterprise Value|X4 Pharmaceuticals, Inc. (XFOR) - Total Company Value|Adicet Bio, Inc. - Value Adjusted for Debt and Cash|Total Company Value Celularity Inc|Real Price to Acquire Entire Company INmune Bio Corporation (INMB)|Enterprise Value BRNS|Enterprise Value kezarlifesciences.com (KZR)|Enterprise Value SABS (SAB Biotherapeutics, Inc.)|AKTX - Real Price to Acquire Entire Company|Enlivex Therapeutics, Ltd. - Enterprise Value|Total Enterprise Value Q32 Bio Inc.|GOVX (GeoVax Labs, Inc.) - Real Price to Acquire Entire Company|edesabiotech.com (EDSA) - Enterprise Value|Real Price to Acquire Entire Company IBIO|CARM (Carisma Tx) - Aggregate Business Value|Enterprise Value XTLB|Company Buyout Price boltbio.com|Enterprise Value HCWB (HCW Biologics)|APVO - Real Price to Acquire Entire Company|AIM ImmunoTech Inc. - Enterprise Value|ADTX - Enterprise Value|GRI Bio Corp (GRI) - Total Company Value|XRTX (XORTX Corp) - Total Company Value|Total Company Value Vyome Holdings Inc|revbiosciences.com (REVB) - Company Buyout Price|Total Company Value Indaptus Therapeutics, Inc. (INDP)|Enterprise Value Scinai Immunotherapeutics Ltd (SCNI)|Total Company Value CalciMedica CALI|AFMD: Business Value|ALLK - Total Company Value|Company Buyout Price HOOKIPA Pharma Inc. HOOK|IGMS: Enterprise Value|iTeos Therapeutics Inc (ITOS) - Enterprise Value|Total Company Value Ocean Bio|TC BioPharm Ltd - Full Business Value|Enterprise Value THRD